Prostate Health*
Standardized to contain: 85-95% fatty acids and biologically active sterols

PRODUCT IS ALSO KNOWN AS
Serenoa repens, Sabal serrulata

PRODUCT DISCUSSION
Saw Palmetto has earned its clinical reputation as the leading herb for supporting men’s prostate and urinary health through the publication of multiple trials that support its efficacy when orally administered. Physiologics Researchers and Chemists have meticulously scrutinized the scientific literature to develop a premier prostate supplement that separates itself from the competition as will be evidenced within this review.*

STRUCTURE AND FUNCTION
The prostate is a sex gland in men, located at the neck of the bladder and urethra. It is under direct control of an enzymatically altered form of male sex hormone at the level of the prostatic androgen receptor. One of the main functions of the prostate gland is to secrete a thin, milky fluid containing citrate and calcium, which contributes to semen production. This fluid has a pH range of 6.5 to 7.5 and may help to neutralize the acidic fluid of the vas deferens.

Saw Palmetto is an extremely popular herb for prostate health, mostly due to the breadth of scientific evidence supporting its biochemical role in the prostate. The American Botanical Council has reported that Saw Palmetto is one of the top 10 selling herbs in the United States. Saw Palmetto extract consists of a dark-brown liquid which is insoluble in water and miscible with fatty oils and fat-soluble organic solvents. Typical fatty acid assays reveal presence of caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, cis-linoleic acid, and linolenic acid. Lauric, myristic and oleic acid are found in the highest amounts.

Saw Palmetto is believed to non-selectively interact with prostate receptor cells through various sub-types. Enzymatic interactions most likely occur within 5-alpha reductase. This mechanism of action has been demonstrated through in-vitro experiments with human fibroblasts. Studies with eukaryotic (baculovirus-directed insect cell) expression system found that LESP (liposterolic extract) interacts with both isoenzymes of 5a-reductase. The clinical USP monograph for Saw Palmetto reports that Saw Palmetto was tested for its interaction with human prostatic a 1-adrenoceptors and [3H]prazosin binding to cloned human a 1A-and a 1B-adrenoceptors in rat-1 cells. All saw palmetto extracts had desired interactions for radioligand binding to human alpha1-adrenoceptors in a non-competitive, concentration-dependent manner. These biological interactions may be the key behind the invivo reports of healthy prostate and urinary function in men supplemented with Saw Palmetto.*

INDICATIONS
As the baby boomer generation grows older, more men will be seeking healthy alternatives to support their prostate and urinary function. In fact, the National Kidney and Urologic Information Clearinghouse reports that over 50% of mature men may be viable candidates for prostate health support. Physiologics Saw Palmetto Standardized Extract is the preferred choice for this population. Raw materials undergo rigorous in-house testing and screening to ensure confirmation with USP standards for fatty acid content and biologically active sterols, and are certified by chemists in the Quality Control division. This confirmation with clinically-defined standards is the key to promoting prostate and urinary health as evidenced in published, human trials.*

HOW CLIENTS MAY BENEFIT

• Utilizing the #1 herbal supplement, both in terms of clinical evidence and popularity among the general public, for prostate health.*
• Promoting urinary health for men.*
• Supplementing with a prostate formula that offers a wide range of active liposterolic extracts and natural constituents.*
• The extract distinguishes itself from many other products through in-house testing using clinically defined chemical analysis methods for measuring and certifying fatty acid and active sterol content, as defined by the United States Pharmacopeia. Clients can rest assured they are receiving a premier product.
• Comes in a convenient, easy to swallow softgel that encourages compliance with dosing regimen.*
• Suitable for a wide-range of clients due to its free of status for yeast, wheat, milk or milk derivatives, lactose, preservatives, soy, artificial color, flavor and sodium (less than 5 mg per serving) as certified through analysis of raw material specification sheets.

CLINICAL EVIDENCE

• A double-blind, placebo controlled study was conducted in men over the age of 45 years old. Saw palmetto, standardized for at least 85% fatty acids and sterols, was administered at daily dosages of 320 mg. Statistical analysis, utilizing two-tailed Mann-Whitney U test and Student’s test, revealed that Saw Palmetto achieved significant effects for prostate health scores as well as urinary health. The researchers noted that results of the study should be applied to supplements with high quality control standards and with standardized contents.
• A double-blind, randomized trial compared the efficacy of Saw Palmetto administered at daily dosages of 320 mg or 480 mg. Analysis found that the lower daily dosage (the dosage supplied by Physiologics Saw Palmetto) was as effective as the higher dosage for prostate health.

SUMMARY
When seeking an herbal alternative which will provide first-class prostate and urinary health for your clients, it is recommended that the supplement be backed by clinical studies published in peer-reviewed journals, be administered in dosages consistent with the scientific literature, consist of active ingredients used in human trials that are backed by chemical analysis methods approved by the highest scientific organizations, and be suitable for a wide range of clients based on its "free of" certification from raw material analysis. Physiologics Saw Palmetto Standardized Extract meets and/or exceeds all of these recommendations.*

SUGGESTED DOSAGE
For adults, take one (1) softgel twice daily, preferably with a meal, or follow the advice of your health care professional. As a reminder, discuss the supplements and medications you take with your health care providers.

REFERENCES
Adriazola Semino M, Lozano Otega JL, Garcia C, et al. Symptomatic treatment of benign hypertropy of the prostate. Comparative study of prazosin and Serenoa repens. Arch Esp Urol 1992; 45: 211-3.

Authie D, Cauquil J. Evaluation of the efficacy of permixon in daily practice. Comptes Rendus de Therap. 1987; 56; 1-9.

Bach D, Ebeling L. Long-term drug treatment of benign prostatic hyperplasia - results of a protective 3-year multicenter study using Sabal extract IDS 89. Phytomed 1996; 3: 105-11 (originally published in Urologe [B]) 1995; 35: 178-83.

Boccafoschi C, Annoscia S. Confromto fra estratto di Serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983; 50: 1257-68.

Braeckman J, Denis L, de Laval J, et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997; 9: 247-59.

Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994; 55: 776-8.

Breau W, Stadler F, Hagenlocher M, et al. Der Sabalfrucht-extrakt SG 291. Ein phytotherapeutikumzur behandlung der benignen prostatahyperplasie. Zeitschrift fur Phytotherapie 1992; 13: 107- 15.

Brown, D. Saw palmetto extract-efficacy shown in long-term study. Townsend Letter for Doctors & Patients. 1997: 160-161.

Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29: 231-40.

Carreras JO. Experience with the hexane extract of Serenoa repens in the treatment of benign prostate hyperplasia. Arch Esp de Urol 1987; 40(5); 310-3.

Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461-2.

Champault, G. et al. The medical treatment of prostatic adenoma. Ann. Urol. 1984. 6:407-410.

Cukier J, Ducassou J, Le Guillou M, et al. Permixon® versus placebo. Résultats d´une étude multicentrque. CR Ther Pharmacol Clin 1985; 4(25): 15-21.

Dathe G, Schmid H. Phytotherapy of benign prostatic hyperplasia (BPH) with extractum Serenoa repens. Urolog B 1991; 31; 220-3.

Delos S, et al. Inhibition of the activity of ’Basic’ 5a-reductase (type 1) detected in Dells and expressed in insect cells. J Steroid Biochem. 1994; 48(4): 347-52.

Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon®in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9: 291-7.

Emili E, Lo Cigno M, Petrone U. Risultati clinici su un nuovo farmaco nella terapia dell´ipertrofia della prostata (Permixon®). Urologia 1983; 50: 1042-8.

Fetrow, C.W. and Avila, JR, Saw palmetto. Professional’s Handbook of Complementary & Alternative Medicines. 1999. Springhouse Corp. Springhouse, PA. 578-582.

Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998; 51(6): 1003-7.

Gerber, G., et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001. 580(6); Dec: 960-965.

Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995; 48: 97- 103.

Kondás J, Philipp V, Diószeghy G. Sabal serrulata extract (Strogen forte®) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 1996; 28: 767-72.

Lininger, S. et al. Saw Palmetto. The Natural Pharmacy. Prima Publishing, Rocklin, CA. 1998: 306- 307.

Lobelenz J. Extractum sabal fructus in the therapy of benign prostatic hyperplasia (BPH). Tpk therapeutikon. 1992; 6; 34-37.

Lowe FC, Robertson C, Roehrborn C, Boyle P. Meta analysis of clinical trials of Permixon. J Urol 1999; 159(5) Suppl: 257.

Marks LS. et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000 May;163(5):1451-6

Marks, L.S. et al. Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology. 1999. 53: 457-461.

Wilt, T.J. Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA. 1998. 280 (18); Nov: 1604-1608.

Mandressi A, Tarallo U, Maggioni A, et al. Terapia medica dell´adenoma prostatico: confronto dellaefficacia dell´estratto di Serenoa repens (Permixon®) versus l´estratto di Pigeum africanum e placebo. Urologia 1983; 50: 752-8.

Mattei FM, Capone M, Acconcia A, et al. Medikamentöse therapie der benignen mit einem extrakt der Sögepalme. TW Urol Nephrol 1990; 2(5): 346-50.

McPartland JM, Pruitt PL. Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study. J Am Osteopath Assoc. 2000 Feb;100(2):87.

Overmyer M. Saw palmetto shown to shrink prostatic epithelium. Urology Times 1999; 24(6):1,42.

Redecker KD, Funk P. Sabal extract WS 1473 in benign prostatic hyperplasia. Extracta Urologica 1998; 21: 24-6.

Reese Smith H, Memon A, Smart CJ, et al. The value of Permixon® in benign prostatic hypertrophy. Br J Urol 1986; 58: 36-40.

Silverio, F. et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur. Urol. 1992. 21:309-314.

Snow, J. Serenoa repens bartram (Palmae). The Protocol Journal of Botanical Medicine. 1996: 15-16.

Sultan, C. et al. Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J. Steroid Biochem. 1984. 20(1):515-519.

Tasca A, Barullli M, Cavazzana A, et al. Treatment of obstructive symptomatology in prostatic adenoma with an extract of serenoa repens. Minerva Urologica e Nefrologica 1985; 37: 87-91.

Vahlensieck W, Völp A, Lubos W, et al. Benign prostatic hyperplasia - treatment with Sabal fruit extract. A surveillance study on 1334 patients. Fortschr Med 1993; 111: 323-6.

Weisser H, Behnke B, Helpap B, et al. Enzyme activities in tissue of human benign prostatic hyperplasia after three months’ treatment with the Sabal serrulata extract IDS 89 (Strogen®) or placebo. Eur Urol 1997; 31: 97-101.

Wilt T J, Ishan A. Stark G, et al. Saw palmetto extracts for treatment of Benign prostatic hyperplasia. JAMA 1998; 280(18): 1804-9.

Ziegler H, Holscher U, et al. Efficacy of saw palmetto fruit special extract WS 1473 in patients with Alken stage I-II benign prostatic hyperplasia - open multicentre study. Jatros Uro 1998; 14: 2-7.

Click here for Label Information in PDF format
Close PDF window to return to store